Results 21 to 30 of about 704,542 (298)

The Definition and Role of Quality of Life In Germany's Early Assessment of Drug Benefit [PDF]

Value in Health, 2014
This study was financially supported by Janssen-Cilag GmbH, Neuss, Germany. We thank Luise Geithner, Joris Lehmann, and Nicole Wehber for their help with data collection. EARLY DRUG BENEFIT ASSESSMENT (EBA) Since January 2011, pharmaceutical manufacturers are obliged to submit dossiers presenting benefits over comparative treatment when launching new ...
Lohrberg, D., Augustin, M., Blome, C.
openaire   +2 more sources

“Market withdrawals” of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations

Health Economics Review, 2018
Background According to the AMNOG act, the German Federal Joint Committee (G-BA) determines the additional benefit of new medicines as a basis for subsequent price negotiations.
Thomas R. Staab, Miriam Walter, Sonja Mariotti Nesurini, Charalabos-Markos Dintsios, J.-Matthias Graf von der Schulenburg, Volker E. Amelung, Jörg Ruof   +6 more
doaj   +1 more source

Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer [PDF]

Geburtshilfe und Frauenheilkunde, 2017
AbstractOncologic therapy is currently undergoing significant changes. A number of innovative targeted medications currently in clinical development have raised high expectations. With that in mind, discussions about terms such as “clinical benefit” and “clinical relevance” are highly topical.
Möbus, Volker, Hell, Susanne, Schmidt, Marcus   +2 more
openaire   +2 more sources

Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree

Health Economics Review, 2019
Background The purpose of this study was to analyse the impact of commissioned addenda by the Federal Joint Committee (FJC) to the HTA body (IQWiG) and their agreement with FJC decisions and to identify potential additional decisive factors of FJC ...
C. M. Dintsios, F. Worm, J. Ruof, M. Herpers   +3 more
doaj   +1 more source

Qualitative assessment of innovations in healthcare provision

BMC Health Services Research, 2009
Background The triad of quality, innovation and economic restraint is as important in health care as it is in the business world. There are many proposals for the assessment of quality and of economic restraints in health care but only a few address ...
Ghosh Amit K, Porzsolt Franz, Kaplan Robert M   +2 more
doaj   +1 more source

Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer [PDF]

, 2012
PMID: 23127367 [PubMed - indexed for MEDLINE] Free full text Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.Peer ...
Royle, J., C Robertson, Pickard, R., C Ramsay, Close, A, Jia, X., Fraser, C., Armstrong, N, Royle, J, Rushton, S P, Robertson, C., Ramsay, C, D Jenkinson, Gurung, T, Lam, T B, Mowatt, G, Fraser, C, Neal, D. E., Rushton, S. P., Armstrong, N., Eden, C. G., MC Robinson, Jenkinson, D, Robinson, M. C., CG Eden, Vale, L, Sharma, P., MDF Shirley, DA Barocas, Lam, T. B., Sharma, P, J Royle, Neal, D E, L Vale, Close, A., Barocas, D A, Robinson, M C, A Close, Robertson, C, TB Lam, DE Neal, Ramsay, C. R. (Craig R.), Gurung, T. (Tara), Mowatt, G., C Fraser, Shirley, M D F, SP Rushton, N Armstrong, Pickard, R, Eden, C G, Barocas, D. A., P Sharma, Vale, L. (Luke), Jenkinson, D., T Gurung, R Pickard, Soomro, N., G Mowatt, Shirley, M. D. F., Jia, X, Soomro, N, N Soomro, X Jia   +62 more
core   +1 more source

Quantitative Benefit–Risk Assessment of COVID-19 Vaccines Using the Multi-Criteria Decision Analysis

Vaccines, 2022
In the early SARS-CoV-2 (COVID-19) pandemic, four major vaccines were approved despite limited efficacy and safety data through short regulatory review periods. Thus, it is necessary to assess the benefit-risk (BR) profiles of the COVID-19 vaccines.
Kyung-Hwa Son, Sun-Hong Kwon, Hye-Jung Na, Youngsuk Baek, Inok Kim, Eui-Kyung Lee   +5 more
doaj   +1 more source

Concept and application of the probability of pharmacological success (PoPS) as a decision tool in drug development: a position paper

Journal of Translational Medicine, 2023
Background In drug development, few molecules from a large pool of early candidates become successful medicines after demonstrating a favourable benefit-risk ratio.
Chao Chen, Xuan Zhou, Silvia Maria Lavezzi, Usman Arshad, Raman Sharma   +4 more
doaj   +1 more source

States of Uncertainty, Risk–Benefit Assessment and Early Clinical Research: A Conceptual Investigation

Science and Engineering Ethics, 2022
AbstractIt can be argued that there is an ethical requirement to classify correctly what is known and what is unknown in decision situations, especially in the context of biomedicine when risks and benefits have to be assessed. This is because other methods for assessing potential harms and benefits, decision logics and/or ethical principles may apply ...
Antje Schnarr, Marcel Mertz
openaire   +2 more sources

Does Mitigation Save? Reviewing cost-1 benefit analyses of disaster risk reduction [PDF]

, 2014
The benefit-cost-ratio (BCR), used in cost-benefit analysis (CBA), is an indicator that attempts to summarize the overall value for money of a project.
Shreve, Cheney, Shreve, CM, Kelman, I, Kelman, Ilan, Kelman, I., Shreve, Cheney M., C.M. Shreve, Shreve, C.M., I. Kelman   +8 more
core   +1 more source